ALPHAGAN P Rx
Generic Name and Formulations:
Brimonidine tartrate 0.1%, 0.15%; oph. soln; contains purite.
Indications for ALPHAGAN P:
Open-angle glaucoma. Ocular hypertension.
Adults and Children:
<2yrs: not recommended. ≥2yrs: 1 drop every 8 hours.
Severe cardiovascular disease. Hepatic or renal impairment. Depression. Cerebral or coronary insufficiency. Raynaud's phenomenon. Orthostatic hypotension. Thromboangiitis obliterans. Remove soft contact lenses before use; may reinsert 15 minutes later. Monitor for loss of effect. Pregnancy (Cat.B). Nursing mothers: not recommended.
MAOIs: see Contraindications. Caution with CNS depressants, antihypertensives, cardiac glycosides, tricyclic antidepressants. Separate administration of other oph drugs by ≥5 minutes.
Oral dryness, ocular hyperemia, burning, stinging, headache, blurred or abnormal vision, foreign body sensation, fatigue, drowsiness, conjunctival follicles, ocular allergic reactions or pruritus, corneal staining/erosion, photophobia, ocular discomfort or dryness, tearing, upper respiratory symptoms, conjunctival blanching, muscular pain, others.
Soln—5mL, 10mL, 15mL
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics